Added to YB: 2026-02-11
Pitch date: 2025-11-23
LRMR [bullish]
Larimar Therapeutics, Inc.
+1.56%
current return
Author Info
No bio for this author
Company Info
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Market Cap
$425.9M
Pitch Price
$3.52
Price Target
17.50 (+390%)
Dividend
N/A
EV/EBITDA
-1.34
P/E
-1.96
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Larimar Therapeutics, Inc. - $LRMR
LRMR: Developing Nomlabofusp for Friedreich's Ataxia, addressing root cause vs Skyclarys' downstream effects. $1B+ peak sales potential, 3-5x return possible. Risks: anaphylaxis (manageable w/ pre-medication), Phase 3 trial success. Catalysts: 2026 safety updates, accelerated approval late 2026/early 2027, acquisition target.
Read full article (9 min)